November 9, 2009, 8:21 AM CT

Predictive value of lung cancer response on PET scan

A rapid decline in metabolic activity on a PET scan after radiation treatment for non-small cell lung cancer is correlated with good local tumor control, as per a research studypresented by scientists at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting.

In addition, the scientists also observed that the higher the metabolic activity and tumor size on a PET scan before therapy, the more likely a patient is to die from lung cancer.

"PET scanning is an emerging tool of molecular imaging in lung cancer, in contrast to Computerized axial tomography scans and MRI scans which are anatomic imaging," said Maria Werner-Wasik, associate professor of Radiation Oncology at Jefferson Medical College of Thomas Jefferson University, and the study's main author. "It has become an important tool in the assessment of lung cancer staging and assessment of therapy response".

Dr. Werner-Wasik and his colleagues conducted a retrospective analysis of 50 lung cancer patients who received PET imaging before and after radiation treatment. They analyzed the prognostic factors for tumor local failure. They measured the metabolic activity using the maximum Standardized Uptake Value (mSUV). They also measured the tumor size, or the Metabolic Tumor Volume.

The risk of local failure decreased for each unit decline in mSUV by the first post-therapy scan. When in comparison to the pre-therapy PET scan, the mSUV of the primary tumor declined by 72 percent in the by the first post-therapy scan, 76 percent by the second scan......... Posted by: Scott      Read more         Source

October 29, 2009, 11:08 PM CT

Drug-radiation eliminates lung cancer

Scientists at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation.

In a study appearing in the recent issue of Cancer Research, UT Southwestern scientists observed that if they administered BEZ235 before they damaged the DNA of tumor cells with otherwise nontoxic radiation, the drug blocked the pro-survival actions of a protein called PI3K, which normally springs into action to keep tumor cells alive while they repair DNA damage.

Scientists tested this novel therapeutic strategy in mice transplanted with NSCL cancers obtained from patients.

They observed that tumors in the mice treated with BEZ235 alone were significantly smaller than those in mice not given the drug. Eventhough the tumors stopped growing, they did not die.

By contrast, tumors were completely eradicated in mice treated with a combination of BEZ235 and radiation.

"These early results suggest that the drug-radiation combination might be an effective treatment in patients with lung cancer," said Dr. Pier Paolo Scaglioni, assistant professor of internal medicine at UT Southwestern and senior author of the study.

NSCL cancer is a leading cause of cancer-related deaths worldwide. The cancer cells often harbor mutations in a gene called K-RAS. Patients with such K-RAS mutations typically are more resistant to therapy with radiation and have a poor prognosis......... Posted by: Scott      Read more         Source

October 7, 2009, 8:01 PM CT

Why African American lung cancer patients respond differently?

Clinical research out of University Hospitals Case Medical Center has observed that African Americans with a common form of lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to new cancer-fighting drugs. Published online in the Journal of Clinical Oncology, the study by Rom Leidner, MD, and his colleagues report that ethnicity plays a significant role in non-small cell lung cancer (NSCLC) genetics and more personalized therapys appears to be beneficial to cancer patients.

African American patients with NSCLC are significantly less likely than Caucasian counterparts to harbor activating mutations of the epidermal growth factor receptor (EGFR) gene in their cancers, which suggests that common oral EGFR inhibitor drugs, such as Tarceva (erlotinib), are unlikely to yield dramatic remissions. Additionally, cancer biopsy testing revealed that African American patients with NSCLC are significantly more likely to have increased copies of the EGFR gene than Caucasians. Detection of increased copies of the Her2 gene in breast cancer, a gene closely correlation to EGFR, has been the basis for major advances in treatment using drugs which target Her2.

"We are finding that ethnicity may play a significant role in a variety of cancers," says Dr. Leidner, an oncologist with Ireland Cancer Center of University Hospitals Case Medical Center and Visiting Instructor at Case Western Reserve University School of Medicine. "It was already known that a higher proportion of East Asian NSCLC patients harbor mutations of the EGFR gene than Caucasians, and that these mutations are linked to a higher likelihood of major responses to EGFR inhibitors. Before our study, however, surprisingly little data existed for African American patients with this common type of lung cancer."........ Posted by: Scott      Read more         Source

September 15, 2009, 2:41 PM CT

Link Between Protein And Lung Disease

In a development that could lead to a novel approach to the therapy of a devastating lung disease, biochemists at The University of Texas Health Science Center at Houston report they are the first to link the osteopontin (OPN) protein to chronic obstructive pulmonary disease (COPD). Findings appear online and will be in the January 2010 print issue of The FASEB Journal, the journal of The Federation of American Societies for Experimental Biology.

More than 12 million Americans are currently diagnosed with this incurable illness, which is the fourth leading cause of death, the National Heart Lung and Blood Institute reports. In the United States, the term COPD includes two main conditions - emphysema and chronic obstructive bronchitis.

The scientists were able to prevent COPD features in a mouse model by genetically removing osteopontin. To gauge the applicability of their findings to humans, the researchers analyzed the airways of people with COPD and found elevated levels of the protein.

"This is an important crossover study," said Michael Blackburn, Ph.D., the study's senior author and professor in the Department of Biochemistry and Molecular Biology at The University of Texas Medical School at Houston. "Because we can show osteopontin is elevated in people with COPD, this suggests that osteopontin could serve as both an indicator of disease progression and a therapeutic target"......... Posted by: Scott      Read more         Source

June 25, 2009, 6:49 PM CT

Big Tobacco dead by 2047

President Barack Obama's signature on a bill this week to grant the Food and Drug Administration (FDA) regulatory authority over tobacco was historic, and represents a step in the march to eliminate tobacco use in this country by 2047, two national tobacco experts said today (June 25).

The pair published "Stealing a March in the 21st Century: Accelerating Progress in the 100-Year War Against Tobacco Addiction in the United States" in the recent issue of the American Journal of Public Health Michael Fiore and Timothy Baker, director and associate director of the University of Wisconsin-Madison Center for Tobacco Research and Intervention (UW-CTRI), respectively, chart milestones in beating tobacco addiction and map a battle plan to eradicate tobacco use in the next few decades. The scientists analyzed data from the 1960s, when the first systemic tracking of smoking rates began, until the present.

"Numerous observers have claimed over time that tobacco use has plateaued and progress against its use has stalled," the authors write. "However, the remarkable decline in rates of tobacco use since the 1960s belies this claim and underscores the remarkable success of tobacco control efforts to date."

Data from the Centers for Disease Control and Prevention show adults smoking between 1965 and 2007 dropped by an average of one half of one percentage point per year, from 42 percent to the current rate of about 20 percent rate. While this rate of decline hasn't occurred each year, the overall decrease has been quite steady......... Posted by: Scott      Read more         Source

June 4, 2009, 3:33 AM CT

Brain irradiation in lung cancer

A national Radiation Therapy Oncology Group (RTOG) study led by a Medical College of Wisconsin Cancer Center doctor at Froedtert Hospital in Milwaukee has observed that a course of radiation treatment to the brain after therapy for locally advanced non-small cell lung cancer reduced the risk of metastases to the brain within the first year after therapy. The study was presented at the American Society of Clinical Oncology annual meeting in Orlando, June 1.

"With improved therapys for non-small cell lung cancer, patients are living longer and we are seeing more brain metastases," says study author Elizabeth Gore, M.D. "This study compared the efficacy of prophylactic (preventive) cranial irradiation (PCI) vs. observation in these patients, and observed that those not receiving cranial irradiation were two and one-half times more likely to develop brain metastasis than those who did".

The study analyzed 356 patients. While the results did not show a statistically significant difference in survival between the two groups, it did show that PCI significantly decreased the occurence rate of brain metastases during the first year post-treatment. Dr. Gore anticipates that additional study of the impact of PCI --on neuro-psychological function and quality of life in these patients-- will help determine if use of PCI should become standard care......... Posted by: Scott      Read more         Source

June 1, 2009, 5:22 AM CT

Drug combination improves outcome for advanced non-small cell lung cancer

A new, international study observed that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer (NSCLC). Results from the Phase III "ATLAS" trial were presented today by Dr. Vincent Miller of Memorial Sloan-Kettering Cancer Center (MSKCC) at the American Society of Clinical Oncology Annual Meeting.

The goal of the study was to determine whether adding erlotinib (Tarceva), a targeted agent, to maintenance treatment with bevacizumab (Avastin), an agent usually used as a component of therapy for advanced NSCLC would delay disease progression. Maintenance treatment involves using one or more agents of a chemotherapy regimen, but not the entire regimen, to delay disease progression and possibly improve survival after patients have previously received stronger standard chemotherapy, which can have significant side effects.

"This is the first study to show the addition of erlotinib to maintenance treatment prolongs progression-free survival in patients with advanced non-small cell lung cancer," said Dr. Miller, a thoracic oncologist at MSKCC and one of the study's main authors. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research," Dr. Miller added......... Posted by: Scott      Read more         Source

May 15, 2009, 5:02 PM CT

Possible breakthrough drug in lung cancer

Interim Phase II data from the LUX-Lung 2 study suggest BIBW 2992 has anti-tumor activity in advanced, second-line, non-small cell lung cancer (NSCLC) patients who have epidermal growth factor receptor (EGFR) mutations.

"Lung cancer kills more people than any other cancer.3 The LUX-Lung 1 and 2 studies represent an opportunity to investigate BIBW 2992 across a range of different patient populations," said Dr. Manfred Haehl, corporate senior vice president, Medicine, Boehringer Ingelheim. "The preliminary data from the LUX-Lung 2 study suggests that BIBW 2992 may have activity in the second-line setting among NSCLC patients with EGFR mutations, which is encouraging news".

BIBW 2992 is an orally-administered, irreversible dual inhibitor of the epidermal growth factor receptor (EGFR) and human epithelial receptor 2 (HER2) tyrosine kinases.1 It is the first irreversible EGFR-TKI (tyrosine kinase inhibitor) to reach Phase III for third/fourth-line NSCLC.

In the emerging era of personalized cancer medicine, Boehringer Ingelheim is one of the first companies to prospectively identify appropriate patients for clinical trials based on biomarkers. As part of the LUX-Lung clinical development program, Boehringer Ingelheim is evaluating BIBW 2992 in NSCLC patients who test positive for EGFR activating mutations......... Posted by: Scott      Read more         Source

May 4, 2009, 5:19 AM CT

Personalized treatment for early lung cancer

Cancer vaccines and targeted therapies are beginning to offer new therapy options following surgery for patients with early stages of lung cancer, experts said at the first European Multidisciplinary Conference in Thoracic Oncology (EMCTO) in Lugano, Switzerland (1-3 May 2009).

"Personalizing treatment is the key strategy for longer and better survival in lung cancer," said Prof Paris Kosmidis, head of the second Medical Oncology Department at Hygeia Hospital in Athens, Greece. "This is especially important for early stage disease when following surgery, decisions about preventive treatment are based on specific prognostic and predictive factors."

Prof Walter Weder, head of thoracic surgery at the University of Zurich in Switzerland, adds: "At the meeting, several research groups will present data from new and ongoing studies that show how existing therapys might be combined with targeted therapies and new cancer vaccines. We hope that these new therapys will provide further progress."

In one poster presentation at the meeting, scientists describe the results of a study that sought to identify which patients are likely to benefit from an immune-boosting vaccine designed to help the immune system recognize MAGE-A3, a protein that is expressed on about 30% of lung cancers......... Posted by: Scott      Read more         Source

April 27, 2009, 5:03 AM CT

Improving treatment of lung cancer

Prevention, personalized therapies and closer collaborations between surgeons, medical oncologists and radiation oncologists will result in better outcomes for patients with lung cancer and those at risk, a leading European expert says.

"Lung cancer is a complex disease. It is one of the most complex cancers, and the more we learn about the biology of the disease, the more we realize that improved cancer care will result from multidisciplinary therapy," said Prof Robert Pirker, from the Medical University of Vienna, Austria.

Prof Pirker is co-chair of the scientific committee of a new medical conference, the European Multidisciplinary Conference in Thoracic Oncology (EMCTO), being held for the first time this year, 1-3 May, in Lugano, Switzerland. The conference aims to further clinical and scientific cooperation between disciplines to help in the fight against lung cancer.

Over the past 5 years, scientists have established that for patients with operable cancer, surgery followed by chemotherapy can result in good outcomes. Now, large clinical trials are beginning to evaluate that adding molecular targeted therapies can further improve the chance of a successful outcome for some patients. In addition, doctors are now attempting to refine their therapys based on the clinical characteristics of individual patients, and based on the molecular profile of their tumour......... Posted by: Scott      Read more         Source

March 18, 2009, 5:19 AM CT

Lung cancer: Molecular scissors in action

In the past few years, many anti-cancer drugs have been developed which are directed selectively against specific key molecules of tumor cells. Among these is an antibody called cetuximab, which attaches to a protein molecule that is found in large amounts on the surface of a number of types of cancer cells. When this surface molecule, called epidermal growth factor receptor, or EGF-R for short, is blocked by cetuximab, the cancer cell receives less signals stimulating cell division.

Clinical studies of non-small cell lung cancer, which is the most frequent type of lung cancer, have shown so far that only part of the patients treated with cetuximab benefit from the therapy. Therefore, doctors are urgently searching for biomarkers which reliably predict responsiveness to the antibody treatment.

Professor Heike Allgayer heads the Department of Experimental Surgery of the Mannheim Medical Faculty of the University of Heidelberg and the Clinical Cooperation Unit "Molecular Oncology of Solid Tumors" at DKFZ. The scientist suspects that the therapeutic antibody can disarm, in particular, individual cancer cells that have detached from the primary tumor, invade other tissues and grow into secondary tumors there. Therefore, Allgayer and her team focused on lung cancer cells' ability to metastasize. Indeed, the researchers were the first to show in lung cancer cell lines that cetuximab inhibits growth and invasion of cancer cells and reduces the frequency of metastasis......... Posted by: Scott      Read more         Source

February 25, 2009, 6:27 AM CT

Smoking and socioeconomic inequities in lung cancer

Europeans with the least education have a higher occurence rate of lung cancer compared with those with the highest education. However, smoking history accounts for approximately half of this risk, as per a research studyin the February 24 online issue of the Journal of the National Cancer Institute.

Prior studies showed that individuals with a lower socioeconomic status have a higher risk for developing lung cancer. Some studies have also suggested that some of the excess risk of lung cancer is due to smoking.

To further investigate the contribution of smoking to the discrepancy in lung cancer incidence, Gwenn Menvielle, Ph.D., and his colleagues examined the association of smoking, diet, education, and lung cancer in 391,251 individuals in the European Prospective Investigation into Cancer and Nutrition study. Menvielle, who conducted the research in The Netherlands at the National Institute for Public Health and the Environment, Bilthoven, and the department of public health of the Erasmus MC, Rotterdam, is now at the Institut National de la Sant et de la Recherche Mdicale in Villejuif, France.

The scientists used participants' highest level of education achieved as an indicator of socioeconomic status and had smoking and diet information from questionnaires completed at study entry......... Posted by: Scott      Read more         Source

January 23, 2009, 6:28 AM CT

Better methods to quit smoking

Scientists from the UK Centre for Tobacco Control Studies led by Dr Linda Bauld at Bath, along with colleagues from the University of Glasgow, have published research in the recent issue of Addiction journal comparing the success and cost-effectiveness of two types of stop smoking support services offered by the NHS. These are community-based group stop smoking support and one-to-one support provided in a pharmacy setting.

The study, funded by the Glasgow Centre for Population Health, NHS Greater Glasgow and Clyde and Health Scotland, observed that more than a third of smokers using support groups quit smoking after four weeks; almost double the proportion of those using a pharmacy-based support scheme to help them quit.

Dr Linda Bauld said: "Smoking is the leading cause of preventable illness and death in the UK, and the single biggest cause of inequalities in health.

"These findings agree with prior research which shows that smokers who used a support group were more likely to quit. But we know that only a very small proportion of smokers using NHS stop smoking services in the UK use this form of help.

"We need to get the message across that group support, combined with stop smoking medications, works well for a number of people.

"However, we observed that both types of service in Glasgow are reaching and treating smokers from disadvantaged areas in substantial numbers, which is extremely encouraging and will contribute to efforts to reduce inequalities in health"......... Posted by: Janet      Read more         Source

January 19, 2009, 11:50 PM CT

Who with lung cancer live longer?

Disparities in survival among black patients diagnosed with early-stage lung cancer are not seen when patients are recommended appropriate therapy, as per a report in the recent issue of Archives of Surgery, one of the JAMA/Archives journals.

Lung cancer causes more deaths in the United States than any other cancer, as per background information in the article. Pulmonary resectionor surgery to remove a portion of the lungprovides the best chance for patients with early-stage disease to be cured. "Black patients with early-stage lung cancer have lower five-year survival rates than white patients, and this difference in outcome has been attributed to lower rates of resection among black patients," the authors write. "Several potential factors underlying racial differences in the receipt of surgical treatment include differences in pulmonary function, access to care, refusal of surgery, beliefs about tumor spread on air exposure at the time of operation and the possibility of cure without surgery, distrust of the health care system and physicians, suboptimal patterns of patient and doctor communication and health care system and provider biases." Of these, access to care is often considered the most important of factors underlying racial disparities.

Farhood Farjah, M.D., M.P.H., of the University of Washington, Seattle, and his colleagues designed a study to address whether differences in survival persist when evaluating only patients who had been recommended to receive optimal treatment, in this case lung resection. Patients recommended for treatment were considered likely to have "cleared" at least one major hurdle of access to care. The researchers analyzed data from 17,739 patients who were diagnosed with lung cancer between 1992 and 2002 (average age 75, 89 percent white and 6 percent black) and who were recommended to receive surgical treatment. They tracked whether or not the patients underwent surgery, and their overall survival, through 2005......... Posted by: Scott      Read more         Source

January 6, 2009, 8:46 PM CT

Cut down on smoking using nicotine gum

Nicotine gum has been in use for over 20 years to help smokers quit abruptly yet close to two-thirds of smokers report that they would prefer to quit gradually. Scientists from the University of Pittsburgh and GlaxoSmithKline Consumer Healthcare have now observed that smokers who are trying to quit gradually can also be helped by nicotine gum. The results of the first study to test the efficacy and safety of using nicotine gum to assist cessation by gradual reduction are reported in the February 2009 issue of the American Journal of Preventive Medicine

Almost 3300 smokers participated in this double-blind, placebo-controlled study. Participants were enrolled in 27 study sites across the US. Participants were allowed to choose between 2-mg and 4-mg doses of nicotine gum, with the higher doses generally being selected by heavier smokers. Within each dose group, participants were then randomized to receive either the active gum or a placebo, yielding 4 approximately equal groups.

The study assessed initial 24-hour abstinence and 28-day abstinence, and participants were followed up at 6 months to determine overall success rates for quitting. The odds of smokers achieving 24-hour abstinence were 40 to 90% higher using active gum in comparison to placebo, and 2 to 4.7 times higher for attaining 28-day abstinence. At the end of 6 months, while absolute quit rates were somewhat low, the odds of quitting were about 2 to 6 times greater for active gum users as for the placebo users, with a quit rate of 6% in the 4-mg group......... Posted by: Janet      Read more         Source

January 5, 2009, 11:34 PM CT

New Tumor Suppressor genes for Lung Cancer

Cancer and cell biology experts at the University of Cincinnati (UC) have identified a new tumor suppressor that may help researchers develop more targeted drug therapies to combat lung cancer.

The study, led by Jorge Moscat, PhD, appears in the January 2009 issue of Molecular and Cellular Biology.

Proto-oncogenes are genes that play a role in normal cell growth (turnover of cells and tissue) but, when genetically modified, can cause the out-of-control cell division that leads to cancer. Prior research had established that Ras, a proto-oncogene, is abnormally expressed in up to 25 percent of human lung cancers; however, scientists did not understand the specific cellular events by which abnormal Ras expression leads to transformation.

UC scientists sought to define the interim steps that occur in Ras-induced tumor development to better understand the underlying biological mechanisms leading to cancer.

"These interim steps are critical because they help us determine how best to intervene and stop cancer growth along the way," explains Moscat, corresponding author of the study and chair of UC's cancer and cell biology department. "Right now, cancer treatment is delivered with a sledgehammer and it needs to be more like a scalpel so we avoid unnecessary harm to the body"......... Posted by: Scott      Read more         Source

December 31, 2008, 7:14 AM CT

Taking one gene at a time in lung cancer

While examining patterns of DNA modification in lung cancer, a team of international scientists has discovered what they say is a surprising new mechanism. They say that "silencing" of a single gene in lung cancer led to a general impairment in genome-wide changes in cells, contributing to cancer development and progression.

In the January 1, 2009, issue of Cancer Research, a journal of the American Association for Cancer Research, they also report finding a strong link between modification of the key gene, MTHFR, and tobacco use by patients with lung cancer even if the patient had smoked for a short period of time.

The findings reinforce tobacco's link to lung cancer development, but show that deactivating one specific gene through a process known as hypermethylation causes systemic dysfunction, or hypomethylation, in a number of genes, said the study's senior investigator, Zdenko Herceg, Ph.D., head of the Epigenetics Group at the International Agency for Research on Cancer (IARC).

"We observed that tobacco-mediated hypermethylation of MTHFR, and consequent partial or complete silencing of the gene, may trigger global hypomethylation and deregulation of DNA synthesis, both of which may contribute to cancer development," he said.

This methylation process, which involves chemically modifying normal DNA in order to change its activity, is seen as an increasingly important factor contributing to so-called "epigenetic inheritance" in cancer development, Herceg said. An epigenetic event is when non-genetic factors cause a gene to change its expression, and this is different from cancer caused by mutated genes that produce errant protein......... Posted by: Scott      Read more         Source

December 30, 2008, 7:15 AM CT

Food additive may increase speed spread of lung cancer

New research in an animal model suggests that a diet high in inorganic phosphates, which are found in a variety of processed foods including meats, cheeses, beverages, and bakery products, might speed growth of lung cancer tumors and may even contribute to the development of those tumors in individuals predisposed to the disease.

The study also suggests that dietary regulation of inorganic phosphates may play an important role in lung cancer therapy. The research, using a mouse model, was conducted by Myung-Haing Cho, D.V.M., Ph.D., and colleagues at Seoul National University, appears in the first issue for January of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

"Our study indicates that increased intake of inorganic phosphates strongly stimulates lung cancer development in mice, and suggests that dietary regulation of inorganic phosphates appears to be critical for lung cancer therapy as well as prevention," said Dr. Cho.

Lung cancer is the number one cause of cancer deaths in the world and is also the most frequently diagnosed solid tumor. Nonsmall cell lung cancer (NSCLC) constitutes over 75 percent of lung cancers and has an average overall 35-year survival rate of 14 percent. Earlier studies have indicated that approximately 90 percent of NSCLC cases were linked to activation of certain signaling pathways in lung tissue. This study revealed that high levels of inorganic phosphates can stimulate those same pathways......... Posted by: Scott      Read more         Source

December 22, 2008, 5:22 AM CT

Genes that may cause lung cancer

Individuals with particular variants of certain genes involved in metabolizing the most potent carcinogen found in cigarette smoke have an increased risk of developing lung cancer. That is the conclusion of a new study reported in the February 1, 2009 issue of CANCER, a peer-evaluated journal of the American Cancer Society. The study's results may help shed light on how lung cancer develops and could have important implications for preventing smoking-related cancers.

Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is a component of cigarette smoke that has been shown to cause lung cancer in rodents. Certain enzymes act to protect the body from this type of chemical by turning it into nontoxic forms or by transporting it from cells. For example, ATP-binding cassette transporters encoded by genes known as ABCB1 and ABCC1 are involved in eliminating carcinogens from the lungs, protecting them against inhaled toxins.

Scientists suspect that individuals with alterations in these genes might have an increased susceptibility to develop lung cancer. Recently, a team of researchers led by Dr. Daru Lu and Dr. Haijian Wang of the Fudan University in Shanghai identified common variants at the beginning and end of the ABC1 and ABCC1 genes. They then analyzed these variants in 500 lung cancer patients and 517 cancer-free controls in a Chinese population......... Posted by: Scott      Read more         Source

November 17, 2008, 10:22 PM CT

Why only some former smokers develop lung cancer

Canadian scientists are trying to answer why some smokers develop lung cancer while others remain disease free, despite similar changes in lifestyle.

Results were presented at the American Association for Cancer Research's Seventh Annual International Conference on Frontiers in Cancer Prevention Research.

As per the Centers for Disease Control and Prevention, more people die from lung cancer than any other cancer type. In fact, as per 2004 data, more people died from lung cancer than breast, prostate and colon cancers combined.

Smoking is the biggest risk factor for developing lung cancer, even after quitting for long periods of time. "More than 50 percent of newly diagnosed patients with lung cancer are former smokers," said Emily A. Vucic, a graduate student at the British Columbia Cancer Research Centre, Vancouver, B.C. "Understanding why some former smokers develop lung cancer is clearly important to the development of early detection, prevention and therapy strategies".

The scientists studied how DNA methylation contributes to lung cancer development in former smokers. Methylation is an important event regulating gene expression during normal development. As we age and in cancer, proper patterns of DNA methylation become deregulated throwing off the tight control of gene activity that normally exists......... Posted by: Scott      Read more         Source

November 13, 2008, 10:45 PM CT

Proton therapy and concurrent chemotherapy in lung cancer

Patients treated for locally advanced non-small cell lung cancer who receive chemotherapy and proton beam treatment have fewer instances of bone marrow toxicity than patients who receive the standard therapy of intensity-modulated radiation (IMRT) and concurrent chemotherapy, as per scientists from The University of Texas M. D. Anderson Cancer Center.

The findings were reported today at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago. It is the first study to examine the benefits of proton beam treatment and concurrent chemotherapy in advanced patients with lung cancer.

The conventional therapy for locally advanced non-small cell lung cancer is intensity-modulated radiation with concurrent chemotherapy. The majority of patients with lung cancer who receive this treatment are at risk of bone marrow toxicity, a debilitating side effect of therapy that further weakens a patient's already vulnerable immune system. The occurrence of bone marrow toxicity - the reduction of hemoglobin, neutrophils, lymphocytes and white blood cells - results in a patient's inability to withstand aggressive therapy, rendering it less effective. This condition often leads to infection, bleeding, fatigue and even death......... Posted by: Scott      Read more         Source